Page 57 - Read Online
P. 57
Page 673 Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48
126. Conciatori F, Bazzichetto C, Falcone I, et al. Role of mTOR signaling in tumor microenvironment: an overview. Int J Mol Sci
2018;19:2453. DOI PubMed PMC
127. Qi Z, Xu Z, Zhang L, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-
PI3Kα/β/δ treatment. Nat Commun 2022;13:182. DOI PubMed PMC
128. Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients
with prostate cancer. Nat Med 2017;23:551-5. DOI PubMed PMC
